Lipids and renal disease.
Chronic renal disease is accompanied by characteristic abnormalities of lipid metabolism, which appear as a consequence of nephrotic syndrome or renal insufficiency and are reflected in an altered apolipoprotein profile as well as elevated plasma lipid levels. Experimental and clinical studies have suggested a correlation between the progression of renal disease and dyslipidemia. High cholesterol and triglyceride plasma levels have been demonstrated to be independent risk factors for progression of renal disease in humans. The underlying pathophysiologic mechanisms for the relationship between lipid levels and progression of renal disease are not yet fully understood, although there are data that oxidative stress and insulin resistance may mediate the lipid-induced renal damage. In the animal model, lipid-lowering agents seem to ameliorate glomerular damage, preventing glomerulosclerosis and interstitial fibrosis. Although evidence from clinical studies indicates that statin therapy is associated with significant benefit in individuals with established chronic renal failure, whether lipid reduction can slow the renal functional decline awaits a primary renal outcome lipid-lowering therapy study.
Unit of Diabetology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24100 Bergamo, Italy. rtrevisan@ospedaliriuniti.bergamo.it
Roberto
R
Trevisan
Alessandro R
AR
Dodesini
Giuseppe
G
Lepore
D002784:Cholesterol / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D050356:Lipid Metabolism; D008055:Lipids / Q000737:chemistry*; D012307:Risk Factors; D014280:Triglycerides / Q000378:metabolism
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol